Success Metrics

Clinical Success Rate
95.7%

Based on 67 completed trials

Completion Rate
96%(67/70)
Active Trials
1(1%)
Results Posted
73%(49 trials)
Terminated
3(4%)

Phase Distribution

Ph phase_3
29
34%
Ph phase_2
5
6%
Ph phase_4
30
35%
Ph not_applicable
5
6%
Ph phase_1
12
14%

Phase Distribution

12

Early Stage

5

Mid Stage

59

Late Stage

Phase Distribution81 total trials
Phase 1Safety & dosage
12(14.8%)
Phase 2Efficacy & side effects
5(6.2%)
Phase 3Large-scale testing
29(35.8%)
Phase 4Post-market surveillance
30(37.0%)
N/ANon-phased studies
5(6.2%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

94.4%

67 of 71 finished

Non-Completion Rate

5.6%

4 ended early

Currently Active

1

trials recruiting

Total Trials

85

all time

Status Distribution
Active(1)
Completed(67)
Terminated(4)
Other(13)

Detailed Status

Completed67
unknown12
Terminated3
Withdrawn1
Suspended1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
85
Active
1
Success Rate
95.7%
Most Advanced
Phase 4

Trials by Phase

Phase 112 (14.8%)
Phase 25 (6.2%)
Phase 329 (35.8%)
Phase 430 (37.0%)
N/A5 (6.2%)

Trials by Status

unknown1214%
withdrawn11%
completed6779%
suspended11%
recruiting11%
terminated34%

Recent Activity

Clinical Trials (85)

Showing 20 of 85 trialsScroll for more
NCT02969798Not Applicable

Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT)

Recruiting
NCT06099067

Harmonizing RCT-Duplicate Emulations In A Real World Replication Program (HARRP)

Completed
NCT02285985Phase 4

Effects of Saxagliptin on Adipose Tissue Inflammation in Humans

Completed
NCT03199053Phase 3

Study to Evaluate Safety and Efficacy of Dapagliflozin and Saxagliptin in Patients With Type 2 Diabetes Mellitus (T2DM) Aged 10 to Below 18 Years Old

Completed
NCT03936023

Replication of the SAVOR-TIMI Diabetes Trial in Healthcare Claims

Completed
NCT01527747Phase 4

Effects of DPP-4 Inhibition on Triglycerides

Suspended
NCT05347459

Cognitive Protective Effect of Newer Antidiabetic Drugs

Unknown
NCT02917031Phase 4

Mechanistic Evaluation of Glucose-lowering Strategies in Patients With Heart Failure

Completed
NCT02597101Phase 2

Anti-Inflammatory Small Drug Adjunctive Therapy for Type 2 Diabetes

Completed
NCT02407899Phase 4

Protective Effects of Saxagliptin (And Vitamin D3) on β Cell Function in Adult-onset Latent Autoimmune Diabetes

Completed
NCT02419612Phase 3

A 52-week International, Multicenter Trial With a Long -Term Extension to Evaluate Saxagliptin With Dapagliflozin in Combination With Metformin Compared to Glimepiride in Combination With Metformin in Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone

Completed
NCT02481479Phase 4

Saxagliptin and Cardiac Structure and Function

Completed
NCT01548651Phase 4

Effect of Saxagliptin Treatment on Myocardial Fat Content, and Monocyte Inflammation

Terminated
NCT01922817Phase 3

DPP4inhibitors in Type 1 Diabetes

Completed
NCT02613897Not Applicable

ESR-15-11293 - Saxa/Dapa, Safety and Efficacy Study

Completed
NCT02471404Phase 4

Efficacy and Safety of Dapagliflozin and Dapagliflozin Plus Saxagliptin in Combination With Metformin in Type 2 Diabetes Patients Compared With Sulphonylurea

Completed
NCT02024477Phase 4

Effect of Saxagliptin on EPCs as a Cellular Biomarker for Evaluating Endothelial Dysfunction in Early T2DM Patients

Completed
NCT02681094Phase 3

A Multi-Center, Randomized, Double-Blind, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Saxagliptin or Dapagliflozin All Given as add-on Therapy to Metformin in Subject With Type 2 Diabetes

Completed
NCT02280486Phase 4

Efficacy and Safety of Saxagliptin VS. Glimepiride in Chinese T2DM Patients Controlled Inadequately With Metformin

Completed
NCT02315495Phase 3

Combining Saxagliptin and Acarbose to Improve Postprandial Glycaemia in Type 2 Diabetes

Completed

Drug Details

Intervention Type
DRUG
Total Trials
85